Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine[1].
References
[1] Eytan M Stein, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 Jan 25;131(4):387-396. DOI:10.1182/blood-2017-06-789800
